The Experts below are selected from a list of 168 Experts worldwide ranked by ideXlab platform
Gabriela Riemekasten - One of the best experts on this subject based on the ideXlab platform.
-
cd4 foxp3 regulatory t cells prolong Drug Induced Disease remission in nzbxnzw f1 lupus mice
Arthritis Research & Therapy, 2013Co-Authors: Olivia Weigert, Caroline Von Spee, R Undeutsch, L Kloke, Jens Y Humrich, Gabriela RiemekastenAbstract:Introduction The ability to ameliorate murine lupus renders regulatory T cells (Treg) a promising tool for the treatment of systemic lupus erythematosus (SLE). In consideration to the clinical translation of a Treg-based immunotherapy of SLE, we explored the potential of CD4+Foxp3+ Treg to maintain Disease remission after induction of remission with an established cyclophosphamide (CTX) regimen in lupus-prone (NZBxNZW) F1 mice. As a prerequisite for this combined therapy, we also investigated the impact of CTX on the biology of endogenous Treg and conventional CD4+ T cells (Tcon).
-
CD4+Foxp3+ regulatory T cells prolong Drug-Induced Disease remission in (NZBxNZW) F1 lupus mice
Arthritis Research & Therapy, 2013Co-Authors: Olivia Weigert, Caroline Von Spee, R Undeutsch, L Kloke, Jens Y Humrich, Gabriela RiemekastenAbstract:Introduction The ability to ameliorate murine lupus renders regulatory T cells (Treg) a promising tool for the treatment of systemic lupus erythematosus (SLE). In consideration to the clinical translation of a Treg-based immunotherapy of SLE, we explored the potential of CD4+Foxp3+ Treg to maintain Disease remission after induction of remission with an established cyclophosphamide (CTX) regimen in lupus-prone (NZBxNZW) F1 mice. As a prerequisite for this combined therapy, we also investigated the impact of CTX on the biology of endogenous Treg and conventional CD4+ T cells (Tcon).
Curt Tysk - One of the best experts on this subject based on the ideXlab platform.
-
lymphocytic colitis a retrospective clinical study of 199 swedish patients
Gut, 2004Co-Authors: Martin Olesen, Sune Eriksson, Johan Bohr, G Jarnerot, Curt TyskAbstract:Background: Lymphocytic colitis is characterised by chronic diarrhoea and specific microscopic changes in a macroscopically normal colonic mucosa. We report clinical features and treatment outcome in a large patient cohort. Methods: Patients were searched for in 24 Swedish gastroenterology clinics. The biopsy material was reassessed using strict histopathological criteria. Clinical data were obtained from medical notes. Results: Lymphocytic colitis was diagnosed in 199 cases. The female:male ratio was 2.4:1. Median age at diagnosis was 59 (48–70) years. The most frequent symptoms were diarrhoea (96%), abdominal pain (47%), and weight loss (41%). The course was chronic intermittent in 30% of patients, chronic continuous in 7%, and a single attack in 63%, and in these cases the Disease duration was 6 (4–11) months. Seventy nine (40%) patients reported associated Diseases, of which thyroid disorders, coeliac Disease, and diabetes mellitus were the most common. In 34 first or second degree relatives of 24 (12%) patients, a family history of ulcerative colitis, Crohn’s Disease, collagenous colitis, or coeliac Disease was reported. Drug Induced Disease was suspected in 19 (10%) patients. A non-significant peak of Disease onset was seen in December-January. More than 80% of treated patients improved on corticosteroids, including budesonide. Conclusions: A family history of other bowel disorders is a new finding. The sudden onset and single attack of limited duration may support a possible infectious cause in some cases. Drugs may cause lymphocytic colitis.
-
luminal nitric oxide and epithelial expression of inducible and endothelial nitric oxide synthase in collagenous and lymphocytic colitis
Scandinavian Journal of Gastroenterology, 2003Co-Authors: Martin Olesen, Johan Bohr, Curt Tysk, Roelinde Middelveld, Jon O Lundberg, Sune ErikssonAbstract:Lymphocytic colitis (LC) and collagenous colitis (CC) arc newly recognised inflammatory bowel Diseases belonging to the group of microscopic colitides (MC). They are characterised clinically by chronic non-bloody and watery diarrhoea, and a macroscopically normal or near normal colonic mucosa where diagnostic histopathological abnormalities are found.The aims of this thesis were to study the epidemiology of LC and CC in Orebro, the clinical features and outcome of treatment in a large Swedish cohort of patients with LC and the familial occurrence of MC. Further objectives were to study luminal levels of colonic nitric oxide (NO), plasma concentrations of the metabolites nitrate/nitrite and the epithelial expression of inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) in patients with MC and correlate to clinical and histopathological status.Whereas previously thought to be rare Diseases, our epidemiological study in Orebro 1993- 1998 showed that the annual incidence of LC and CC is close to the figures generally reported in Sweden in Crohn's Disease. The combined rates of LC and CC are nearly as high as the incidence of ulcerative colitis. Microscopic colitis was diagnosed in 10% of all patients referred for a colonoscopy due to non-bloody diarrhoea, and in almost 20% of those older than 70 years.The clinical features and outcome of treatment in LC were studied retrospectively in 199 Swedish patients. Diarrhoea was the predominant symptom, followed by abdominal pain and weight loss. Forty percent had at least one associated autoimmune or inflammatory Disease; the most common were thyroid disorder and coeliac Disease. A single attack occurred in 63% with a median Disease duration of six months. In 1 0% a Drug Induced Disease was suspected. A sudden onset of Disease was noted in 25% and a non-significant peak of Disease onset was seen in December-Janumy. The sudden onset, the single attack of limited duration, and the possible seasonality of the Disease's onset may indicate an infectious etiology in some cases.Corticosteroids, prednisolone as well as budesonide, were the most effective therapy in our retrospective LC study and more than 80% of the patients improved short-term. However, the relapse risk was high after withdrawal of therapy. A response rate of 50-70% was noted for loperamide, cholestyramine, metronidazole and mesalazine.A family history of bowel Disease- ulcerative colitis, Crohn's Disease, CC or coeliac Diseasewas reported in 12% of the 199 LC patients, and ulcerative colitis or Crohn's Disease alone in 7%. We also report a familial occurrence of MC in five families, with two affected members in each family. In two families the members had different types of MC whereas in three families they all had CC.Increased plasma levels of nitrate/nitrite and greatly enhanced levels of colonic luminal NO were found in MC patients. The NO levels were associated to the histopathological status and correlated with the clinical activity, indicating that NO is involved in the pathophysiology of MC. Expression of eN OS in the epithelium was not increased in patients with MC. An increased expression of iNOS was seen apically in the surface epithelium in MC patients, and a correlation between the staining intensity of iNOS and luminal NO levels, pointing towards the epithelial cells being the cellular source of the NO production.
Olivia Weigert - One of the best experts on this subject based on the ideXlab platform.
-
cd4 foxp3 regulatory t cells prolong Drug Induced Disease remission in nzbxnzw f1 lupus mice
Arthritis Research & Therapy, 2013Co-Authors: Olivia Weigert, Caroline Von Spee, R Undeutsch, L Kloke, Jens Y Humrich, Gabriela RiemekastenAbstract:Introduction The ability to ameliorate murine lupus renders regulatory T cells (Treg) a promising tool for the treatment of systemic lupus erythematosus (SLE). In consideration to the clinical translation of a Treg-based immunotherapy of SLE, we explored the potential of CD4+Foxp3+ Treg to maintain Disease remission after induction of remission with an established cyclophosphamide (CTX) regimen in lupus-prone (NZBxNZW) F1 mice. As a prerequisite for this combined therapy, we also investigated the impact of CTX on the biology of endogenous Treg and conventional CD4+ T cells (Tcon).
-
CD4+Foxp3+ regulatory T cells prolong Drug-Induced Disease remission in (NZBxNZW) F1 lupus mice
Arthritis Research & Therapy, 2013Co-Authors: Olivia Weigert, Caroline Von Spee, R Undeutsch, L Kloke, Jens Y Humrich, Gabriela RiemekastenAbstract:Introduction The ability to ameliorate murine lupus renders regulatory T cells (Treg) a promising tool for the treatment of systemic lupus erythematosus (SLE). In consideration to the clinical translation of a Treg-based immunotherapy of SLE, we explored the potential of CD4+Foxp3+ Treg to maintain Disease remission after induction of remission with an established cyclophosphamide (CTX) regimen in lupus-prone (NZBxNZW) F1 mice. As a prerequisite for this combined therapy, we also investigated the impact of CTX on the biology of endogenous Treg and conventional CD4+ T cells (Tcon).
Sune Eriksson - One of the best experts on this subject based on the ideXlab platform.
-
lymphocytic colitis a retrospective clinical study of 199 swedish patients
Gut, 2004Co-Authors: Martin Olesen, Sune Eriksson, Johan Bohr, G Jarnerot, Curt TyskAbstract:Background: Lymphocytic colitis is characterised by chronic diarrhoea and specific microscopic changes in a macroscopically normal colonic mucosa. We report clinical features and treatment outcome in a large patient cohort. Methods: Patients were searched for in 24 Swedish gastroenterology clinics. The biopsy material was reassessed using strict histopathological criteria. Clinical data were obtained from medical notes. Results: Lymphocytic colitis was diagnosed in 199 cases. The female:male ratio was 2.4:1. Median age at diagnosis was 59 (48–70) years. The most frequent symptoms were diarrhoea (96%), abdominal pain (47%), and weight loss (41%). The course was chronic intermittent in 30% of patients, chronic continuous in 7%, and a single attack in 63%, and in these cases the Disease duration was 6 (4–11) months. Seventy nine (40%) patients reported associated Diseases, of which thyroid disorders, coeliac Disease, and diabetes mellitus were the most common. In 34 first or second degree relatives of 24 (12%) patients, a family history of ulcerative colitis, Crohn’s Disease, collagenous colitis, or coeliac Disease was reported. Drug Induced Disease was suspected in 19 (10%) patients. A non-significant peak of Disease onset was seen in December-January. More than 80% of treated patients improved on corticosteroids, including budesonide. Conclusions: A family history of other bowel disorders is a new finding. The sudden onset and single attack of limited duration may support a possible infectious cause in some cases. Drugs may cause lymphocytic colitis.
-
luminal nitric oxide and epithelial expression of inducible and endothelial nitric oxide synthase in collagenous and lymphocytic colitis
Scandinavian Journal of Gastroenterology, 2003Co-Authors: Martin Olesen, Johan Bohr, Curt Tysk, Roelinde Middelveld, Jon O Lundberg, Sune ErikssonAbstract:Lymphocytic colitis (LC) and collagenous colitis (CC) arc newly recognised inflammatory bowel Diseases belonging to the group of microscopic colitides (MC). They are characterised clinically by chronic non-bloody and watery diarrhoea, and a macroscopically normal or near normal colonic mucosa where diagnostic histopathological abnormalities are found.The aims of this thesis were to study the epidemiology of LC and CC in Orebro, the clinical features and outcome of treatment in a large Swedish cohort of patients with LC and the familial occurrence of MC. Further objectives were to study luminal levels of colonic nitric oxide (NO), plasma concentrations of the metabolites nitrate/nitrite and the epithelial expression of inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) in patients with MC and correlate to clinical and histopathological status.Whereas previously thought to be rare Diseases, our epidemiological study in Orebro 1993- 1998 showed that the annual incidence of LC and CC is close to the figures generally reported in Sweden in Crohn's Disease. The combined rates of LC and CC are nearly as high as the incidence of ulcerative colitis. Microscopic colitis was diagnosed in 10% of all patients referred for a colonoscopy due to non-bloody diarrhoea, and in almost 20% of those older than 70 years.The clinical features and outcome of treatment in LC were studied retrospectively in 199 Swedish patients. Diarrhoea was the predominant symptom, followed by abdominal pain and weight loss. Forty percent had at least one associated autoimmune or inflammatory Disease; the most common were thyroid disorder and coeliac Disease. A single attack occurred in 63% with a median Disease duration of six months. In 1 0% a Drug Induced Disease was suspected. A sudden onset of Disease was noted in 25% and a non-significant peak of Disease onset was seen in December-Janumy. The sudden onset, the single attack of limited duration, and the possible seasonality of the Disease's onset may indicate an infectious etiology in some cases.Corticosteroids, prednisolone as well as budesonide, were the most effective therapy in our retrospective LC study and more than 80% of the patients improved short-term. However, the relapse risk was high after withdrawal of therapy. A response rate of 50-70% was noted for loperamide, cholestyramine, metronidazole and mesalazine.A family history of bowel Disease- ulcerative colitis, Crohn's Disease, CC or coeliac Diseasewas reported in 12% of the 199 LC patients, and ulcerative colitis or Crohn's Disease alone in 7%. We also report a familial occurrence of MC in five families, with two affected members in each family. In two families the members had different types of MC whereas in three families they all had CC.Increased plasma levels of nitrate/nitrite and greatly enhanced levels of colonic luminal NO were found in MC patients. The NO levels were associated to the histopathological status and correlated with the clinical activity, indicating that NO is involved in the pathophysiology of MC. Expression of eN OS in the epithelium was not increased in patients with MC. An increased expression of iNOS was seen apically in the surface epithelium in MC patients, and a correlation between the staining intensity of iNOS and luminal NO levels, pointing towards the epithelial cells being the cellular source of the NO production.
Martin Olesen - One of the best experts on this subject based on the ideXlab platform.
-
lymphocytic colitis a retrospective clinical study of 199 swedish patients
Gut, 2004Co-Authors: Martin Olesen, Sune Eriksson, Johan Bohr, G Jarnerot, Curt TyskAbstract:Background: Lymphocytic colitis is characterised by chronic diarrhoea and specific microscopic changes in a macroscopically normal colonic mucosa. We report clinical features and treatment outcome in a large patient cohort. Methods: Patients were searched for in 24 Swedish gastroenterology clinics. The biopsy material was reassessed using strict histopathological criteria. Clinical data were obtained from medical notes. Results: Lymphocytic colitis was diagnosed in 199 cases. The female:male ratio was 2.4:1. Median age at diagnosis was 59 (48–70) years. The most frequent symptoms were diarrhoea (96%), abdominal pain (47%), and weight loss (41%). The course was chronic intermittent in 30% of patients, chronic continuous in 7%, and a single attack in 63%, and in these cases the Disease duration was 6 (4–11) months. Seventy nine (40%) patients reported associated Diseases, of which thyroid disorders, coeliac Disease, and diabetes mellitus were the most common. In 34 first or second degree relatives of 24 (12%) patients, a family history of ulcerative colitis, Crohn’s Disease, collagenous colitis, or coeliac Disease was reported. Drug Induced Disease was suspected in 19 (10%) patients. A non-significant peak of Disease onset was seen in December-January. More than 80% of treated patients improved on corticosteroids, including budesonide. Conclusions: A family history of other bowel disorders is a new finding. The sudden onset and single attack of limited duration may support a possible infectious cause in some cases. Drugs may cause lymphocytic colitis.
-
luminal nitric oxide and epithelial expression of inducible and endothelial nitric oxide synthase in collagenous and lymphocytic colitis
Scandinavian Journal of Gastroenterology, 2003Co-Authors: Martin Olesen, Johan Bohr, Curt Tysk, Roelinde Middelveld, Jon O Lundberg, Sune ErikssonAbstract:Lymphocytic colitis (LC) and collagenous colitis (CC) arc newly recognised inflammatory bowel Diseases belonging to the group of microscopic colitides (MC). They are characterised clinically by chronic non-bloody and watery diarrhoea, and a macroscopically normal or near normal colonic mucosa where diagnostic histopathological abnormalities are found.The aims of this thesis were to study the epidemiology of LC and CC in Orebro, the clinical features and outcome of treatment in a large Swedish cohort of patients with LC and the familial occurrence of MC. Further objectives were to study luminal levels of colonic nitric oxide (NO), plasma concentrations of the metabolites nitrate/nitrite and the epithelial expression of inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) in patients with MC and correlate to clinical and histopathological status.Whereas previously thought to be rare Diseases, our epidemiological study in Orebro 1993- 1998 showed that the annual incidence of LC and CC is close to the figures generally reported in Sweden in Crohn's Disease. The combined rates of LC and CC are nearly as high as the incidence of ulcerative colitis. Microscopic colitis was diagnosed in 10% of all patients referred for a colonoscopy due to non-bloody diarrhoea, and in almost 20% of those older than 70 years.The clinical features and outcome of treatment in LC were studied retrospectively in 199 Swedish patients. Diarrhoea was the predominant symptom, followed by abdominal pain and weight loss. Forty percent had at least one associated autoimmune or inflammatory Disease; the most common were thyroid disorder and coeliac Disease. A single attack occurred in 63% with a median Disease duration of six months. In 1 0% a Drug Induced Disease was suspected. A sudden onset of Disease was noted in 25% and a non-significant peak of Disease onset was seen in December-Janumy. The sudden onset, the single attack of limited duration, and the possible seasonality of the Disease's onset may indicate an infectious etiology in some cases.Corticosteroids, prednisolone as well as budesonide, were the most effective therapy in our retrospective LC study and more than 80% of the patients improved short-term. However, the relapse risk was high after withdrawal of therapy. A response rate of 50-70% was noted for loperamide, cholestyramine, metronidazole and mesalazine.A family history of bowel Disease- ulcerative colitis, Crohn's Disease, CC or coeliac Diseasewas reported in 12% of the 199 LC patients, and ulcerative colitis or Crohn's Disease alone in 7%. We also report a familial occurrence of MC in five families, with two affected members in each family. In two families the members had different types of MC whereas in three families they all had CC.Increased plasma levels of nitrate/nitrite and greatly enhanced levels of colonic luminal NO were found in MC patients. The NO levels were associated to the histopathological status and correlated with the clinical activity, indicating that NO is involved in the pathophysiology of MC. Expression of eN OS in the epithelium was not increased in patients with MC. An increased expression of iNOS was seen apically in the surface epithelium in MC patients, and a correlation between the staining intensity of iNOS and luminal NO levels, pointing towards the epithelial cells being the cellular source of the NO production.
